Stockrabit · Analysts
Questions across 21 calls

Neha Manpuria

Firm not listed in source transcripts

Lupin Limited

Lupin Limited CC-May26.pdf · 2026-05-08
How should we think about the US business in the next year given what you mentioned about Tolvaptan and Mirabegron? Do you see any other product launches which could be meaningful? I know it's difficult to sustain this base, but even as we see competition in Tolvaptan and Mirabegron, what sort of product launches should we look for ward to over the next two years which probably gives us the confidence on 25% margin?
My second question is, I think, Ramesh sir mentioned about capital allocation. Given the increase in cash balance which will only go up with this, these US launches, how should we think about capital allocation priorities? I know, you've mentioned this in the past. I just wanted to get a sense of, what we are seeing, in terms of opportunities in the market ? What's interesting you and what are the challenges in terms of not being able to deploy that money?
Lupin Limited CC-Nov25.pdf · 2025-11-07
On gross margins, how should I look at it, given we had a lot of moving parts and benefit in this quarter. From a full -year perspective, based on what happens to Tolvaptan, what should be a reasonable assumption for gross margin levels?
On biosimilars, something like , Pegfilgrastim, which is already a competitive market, Ranibizumab, we've seen players exit because of pricing. What do you think of, how does Lupin see itself positioning competitively to gain market share there? And from a commercial front-end aspect, do we need to spend incrementally to get that infrastructure in place in the next year for Ranibizumab and Pegfilgrastim? And in your assessment, what could be the cost for that?
Lupin Limited CC-Sep24.pdf · 2024-11-08
Ramesh, in your opening remarks, you gave us several reasons for the gross margin improvement that we have seen. And I think that you mentioned you expect the gross margins to maintain at these levels. So, would that be in the first half range that you're seeing in the 69% to 70% or the quarter, just wanted to get a sense on that?
And what according to you has been the biggest driver for the margin improvement that we have seen in the first half? Is it product mix? Is it the input cost? And if you were to pin down, the top two areas where you've seen the most improvement?
Lupin Limited CC-Sep23.pdf · 2023-11-09
Thanks for taking my question. Vinita, if we do think Spiriva ramps-up to 35%- 40% market share in the nex t year. A, would this require, in your view, more pricing action from us, to go after this market share? And second, if that is the case, should we then expect the current base that we've reported to see a step-up over the next few quarters? Because in you r opening comments, I think you mentioned that we'll keep the base at 200 plus, but shouldn't we see a step-up from the current base if we get to the 35%-40%?
Got it. And, I remember you once mentioning that, you think you have enough capacity to get to your fair share. Should I assume the 35% to 40% is the fair share that you were talking about and, capacity is not an issue, therefore you've given that number?

Biocon Limited

Biocon Limited CC-May26.pdf · 2026-05-08
This is Neha from Bank of America. Two questions from me. First, on the biosimilars revenue, given that we spoke about execution in the opening remarks, how should we think about FY '27, FY '28 given we have had some launches in the back end of '26. Also, there was an impact of the planned shutdown that we took in third quarter and a bunch of launches, but we haven't really seen material improvement in biosimilars revenue fourth quarter versus second quarter, if that is a comparable number, given we have also seen market share increases. So, is it fair to assume that full stabilization of that disruption that we saw in the third quarter is not yet done?
Shreehas, I understand you don't want to give specific guidance, but if I were to think about fourth quarter FY '27 exit run rate, given the launches that we have, what in your mind would be a comfortable number based on the launch pipeline?
Biocon Limited CC-Feb26.pdf · 2026-02-13
This is Neha from BofA Securities. First question on the biosimilar business, the upgrade of production and quality that you have mentioned, is it fair to assume that this is largely done and behind us? And second, what led to this need for this upgradation of production? Because these approvals were expected to come through this year. So, any specific reason that drove the upgradation at this point of time?
Shreehas, then how should we think about growth from here? Like you said, that for the full year, we're still guiding mid-20s. Next year, given we have a bunch of these launches that will flow through, should we get back to, you know, the 20 plus percent growth trajectory for the biosimilar business with the mid -20s margin, or should that margin also improve going into next year?

Zydus Lifesciences Limited

Zydus Lifesciences Limited CC-Jun25.pdf · 2025-08-12
Yeah. Thanks for taking my question. My first question is on the 505(b)(2) portfolio that you indicated would ramp up by the end of this year. Currently, we have Sitagliptin . I think there was one more, Docetaxel, that we had in-licensed last year . Are there any other launches in the 505(b)(2) portfolio that is expected as we think about the next year? And how big can the 505(b)(2) portfolio be for Zydus next year?
Besides Sitagliptin , can the other portfolios also , I think, Sita you had mentioned that can be , you know , $50 odd million . So, can 10 of 21 the other products be as large as Sita, or Sita would still end up being the largest product in that portfolio?
Zydus Lifesciences Limited CC-Sep24.pdf · 2024-11-12
Ya, thanks for taking my question. Just on the 2 acquisitions that we announced. The first one, as a part of the wellness business , how big is this business that we acquired and any other details you can give? The second one is on the Perfect Day JV . Is this for the CDMO piece that we are setting up this facility? By when can 7 of 22 we expect commissioning of this facility as a part of the JV that would help please? Dr. Sharvil Patel On the consumer health front, the business that we acquired of RiteBite Max Protein and its range of products is about 130 crores in annual revenue and obviously it allows us to play in the healthy snacking and we have always indicated that we would like to play in the protein malnutrition/nutrition space . So, this gives us a good area to enter. The brand is obviously a market leader in its category with strong growth and continues to be a leader also in all segments, whether it is general trade, ecommerce, modern trade also. So , we are quite excited with the opportunity. With respect to our joint venture related to Perfect Day, it is going to be, I mean in a way, you call it as a CDMO because it is going to do development also. So , it is not only manufacturing but develop and manufacture large scale fermentation of the protein isolate of milk, which is the whey. We do believe that this will be a large global opportunity with large global consumers, who have already tested and have looked at making this as a part of their resilient supply chain. So, we see this as a tremendously large opportunity to have an animal free derived protein product which can also have a significant ESG benefit.
By when can we expect the commissioning of this facility? Any capex that you would want to highlight on the manufacturing facility?
Zydus Lifesciences Limited CC-Dec23.pdf · 2024-02-09
Thanks for taking my question. My first question is on the India growth that we have seen in the quarter. I know you have talked about India starting to see double digit growth over time but was there anything specific in the quarter? How sustainable is this trend as we look at the next year? So that’s the first part of the question on India. Second is, also to maintain this growth momentum, do we think we need to add MRs or continue to invest in the India business to support this double-digit growth?
How many reps are we adding Sir? What is the current strength and how much we are adding?

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited CC-May26.pdf ·
Yes, hi. Am I audible now? For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com,
Okay, sorry about the last time. Just one quick question. You know in terms to revive growth for Organon, besides in-licensing, do you think there would be more investment required you know, either on the biosimilar commercial side or let's say for VTAMA given how competitive that segment is? Have we come to a number in terms of this would be the incremental investment that would be required to revive growth? And you know does given the net debt is at 2x to 2.3x, does this then you know, limit the more acquisitions that we could do on the specialty side for Sun Pharma or for the combined entities, you know, for the next two -three years till the time we consolidate Organon?

Aurobindo Pharma Limited

Aurobindo Pharma Limited CC-Feb26.pdf ·
Thanks for taking my question. My first question is on Lannett. Could you give us an update on where we are in the approval process from the F TC and when should we expect the completion of that transaction? And just to follow up on L annett, you know, in your view, what would be the rough overlap between the L annett portfolio and Aurobindo portfolio that, you know, F TC could probably look at?
Understood. So, I should assume that, you know, there is no risk from an FTC perspective in terms of timelines for the closure of this deal?
Aurobindo Pharma Limited CC-Mar25.pdf ·
Yeah, thanks for taking my question. First question on the US business. I know you're not giving the breakup of the US anymore, but just wanted to understand improvement in both the base business in the injectable as well as the oral solid. Is it fair to assume that the injectable business has gone back to pre-disruption levels Unit 4 [Eugia Unit- 3] disruption levels in this quarter?
And Yugandhar, how should I think about growth for the injectables? I mean, you know, given that Unit 4 [Eugia-3] hasn't been cleared as yet ? How do we see growth in the Eugia business, as Revlimid also goes away? So just some colour there.
Aurobindo Pharma Limited CC-Jun25.pdf ·
Yeah, thanks for taking my question. You know, two questions on the U.S. business. Swami Sir, if I look at the oral solid business, could you quantify how much would be this de-stocking impact just to understand, you know, how the business is done both from a year-on-year and a quarter-on-quarter perspective?
Understood. And then I'm just wondering about the, you know, U.S. business decline quarter-on-quarter and, you know, Yugandhar Sir’s comment that the injectable business seems to be improving. If it's just 15 days of, you know, 15 days or one month of de-stocking, you know, the entire, you know, 550 crores decline quarter-on- quarter is just Revlimid? I mean, if I were to look at the last quarter injectable base or Eugia base that we used to mention, it seems like the ex-Revlimid business isn't actually showing as much improvement or, you know, normalcy as, you know, what we seem to be leading. So what am I missing here in the U.S. business?
Aurobindo Pharma Limited CC-Nov25.pdf ·
Yeah, thanks for taking my question. My first question is on Pen-G. Subbu Sir, what would be the EBITDA loss contribution from Pen -G at the moment? And at what level do we breakeven on the Pen -G plant? And, second, let's say this MIP representation does not come through or gets delayed, what's the Plan B in terms of achieving breakeven? Does that impact our ability to ramp up the plant even if MIP gets delayed or does not come through?
Sorry to harp on this, Subbu Sir, but what would be given where prices are for Pen-G and Pen-G allied products, are we still cost competitive if we get to 8,000 tons per month [800 per month] production levels? Will we still be cost competitive?
Aurobindo Pharma Limited CC-Jun24.pdf ·
Thanks for taking my question. Yugandhar, m y first question is on the US business. I thought we were supposed to see improvement in the US business with the resumption of the facility in the quarter. Could you give us some colour on what's happening to that? Should we expect the improvement in the injectable business to be a little slower versus our initial expectation ? And just an extens ion to that question. We've seen another facility get an OAI for the injectable business. You know, how are you thinking about compliance for the injectable business, given that's a key for our growth momentum in Eugia?
And does that make us confident to be able to gain the lost market share for these injectable products? Because I can see that we have lost market share in some of the products in the injectable side.
Aurobindo Pharma Limited CC-Dec24.pdf ·
Yeah. Thanks for taking my question. S wami Sir, you know the 2 billion units in China that will free up capacity probably in the India manufacturing for the U .S. market and the fact that we're also adding capacity in Raleigh, etc ., you know how much additional capacity would you have for the U .S. market going into next year and how confident are we of being able to actually capitalize on that without necessarily putting pressure on the market given how large we've become in the U.S.?
Understood. So, we don't see a situation where the additional capacity in India you know does not necessarily get absorbed in the U.S. We have that much of visibility?